Monetary Management Group Inc. bought a new position in shares of AstraZeneca PLC (OTCMKTS:AZNCF – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 6,250 shares of the company’s stock, valued at approximately $1,097,000.
Other large investors have also recently added to or reduced their stakes in the company. L & S Advisors Inc bought a new stake in AstraZeneca during the fourth quarter worth approximately $14,863,000. Burling Wealth Partners LLC bought a new stake in AstraZeneca during the fourth quarter worth approximately $4,532,000. Hendley & Co. Inc. bought a new stake in AstraZeneca during the fourth quarter worth approximately $11,373,000. Saranac Partners Ltd bought a new stake in AstraZeneca during the third quarter worth approximately $876,000. Finally, Root Financial Partners LLC bought a new stake in AstraZeneca during the fourth quarter worth approximately $622,000. 40.87% of the stock is currently owned by institutional investors.
AstraZeneca Stock Performance
Shares of OTCMKTS:AZNCF opened at $187.10 on Tuesday. AstraZeneca PLC has a 1-year low of $122.26 and a 1-year high of $195.00. The company has a 50 day moving average price of $187.10 and a 200 day moving average price of $185.82.
AstraZeneca Profile
AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.
The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.
Featured Articles
- Five stocks we like better than AstraZeneca
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Want to see what other hedge funds are holding AZNCF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (OTCMKTS:AZNCF – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
